Boston Scientific's CHAMPION-AF Trial Meets All Endpoints for WATCHMAN FLX

Boston Scientific Corporation announced that its CHAMPION-AF clinical trial for the WATCHMAN FLX device successfully met all primary and secondary safety and efficacy endpoints. The study demonstrated that the device provides statistically superior protection against bleeding compared to traditional blood thinners in patients with non-valvular atrial fibrillation. These findings were presented at the ACC.26 conference and simultaneously published in the New England Journal of Medicine (NEJM). The trial positions the WATCHMAN FLX as a viable first-line therapy for stroke risk reduction, potentially replacing long-term oral anticoagulants. This clinical milestone is expected to be a significant long-term growth driver for the company's cardiovascular portfolio. Investors view the results as a major step in expanding Boston Scientific's market share within the medical device industry.

Sources:prnewswire.comnews.bostonscientific.comtctmd.commarketscreener.cominvesting.comgurufocus.comprnewswire.combusinesswire.comstocktitan.netherzmedizin.deacademic.oup.combarchart.commarketscreener.combioworld.comintellectia.ainews.bostonscientific.comnationaltoday.comintellectia.aiainvest.cominvesting.commarketscreener.comainvest.comnationaltoday.comwww.pharmiweb.comalphagalileo.org